Ipsita Smolinski


A New, Republican CMMI?

As the repeal and replacement of the Affordable Care Act winds its way through Congress, one of the more popular parlor games in Washington these days is guessing what a post-ACA world will look like.

Drug Pricing in a Trump America

The pharmaceutical industry breathed a sigh of relief when Donald Trump was declared the next president of the United States. While not a wholly known entity, the devil the industry knew was a lot scarier than the devil it didn’t know. Hillary Clinton had spelled danger.

The Public Plan Endgame

In the face of rising premiums and carrier exodus from markets across the country, leading Democrats and presidential candidate Hillary Clinton have expressed support for a public plan option for health insurance. Supporters say that a government-run plan would provide stability to the fragile – many would say “failing” – state health insurance exchanges.

Can 21st Century Cures Get a Fair Shake in an Election Year?

The 21st Century Cures Act is an amalgam of ideas with one objective: improving the laborious process of moving medical innovation from the lab to patients’ bedsides. Two years in the making, this bipartisan effort — like any other in Washington — has been amended by compromise and political expedience.

Value Frameworks Are Expanding For Drugs & Devices

  There’s no question many cancer drugs and specialty pharmaceuticals are expensive, and their benefits often vary from patient to patient. Several years ago, a number of non-government organizations (NGOs) began launching “value frameworks” to help patients and payers decipher which drugs and devices may be most beneficial – and to provide guidance on appropriate […]

Not Waiting for the Feds, Some States Are Tackling Drug Pricing

  Like the rest of the country, Californians will head to the polls on Nov. 8 to vote for a new President and Congress.  The liberal state is also known for offering a laundry list of ballot initiatives each election cycle covering issues ranging from agriculture to the entertainment industry to healthcare. This year, Golden State […]

Will Health Plan Mega-Mergers Upend Pharma?

  For over a year, surveys have shown that Americans are fed up with high drug prices. Now, presidential candidates are talking about solutions on the campaign trail.  A new administration is likely to “do something” on reducing the cost of drugs. Politicians have readied their arrows, but could another group create an additional battlefront […]

Are Consumer Genomics Taking Off?

23andMe, a consumer-level genetic testing company, launched the consumer genomics movement with a bang. But in late 2013, regulatory setbacks forced it to stop marketing its direct-to-consumer genetic test kits. The hiatus lasted until three months ago, when the company received FDA approval to restart sales of its “personalized genetic reports.” Speaking on a panel […]

Has DC Crossed the Rubicon in Curbing Drug Prices?

Drug companies will have to think twice before pricing new medications. Public outrage over higher and higher prices has reached a boiling point. Seventy-two percent of Americans believe drug costs are unreasonably high, according to a recent Kaiser Family Foundation poll. This September, Democratic presidential frontrunner Hillary Clinton echoed the public’s sentiment with a drug […]

2016 Obamacare Preview: Heading into Open Season

November 1 marks the start of 2016 open enrollment for Affordable Care Act health plan marketplaces. So far, it looks like a mixed bag for both the Obama Administration and insurers. More than 17 million people have gained health insurance coverage through the ACA marketplace plans, Medicaid or the individual market as a result of […]